Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NanoMed Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

The idea of delivering drugs encased in lipids was a popular one in the early days of the biotechnology industry but manufacturing problems pushed lipid-based drug delivery from favor. NanoMed Pharmaceuticals thinks it has found a way to get lipids to fulfill their potential as delivery vehicles, shielding the drugs they contain from cellular mechanisms responsible for drug resistance. The start-up aims to leverage its know-how to treat cancers notoriously resistant to chemotherapy.

You may also be interested in...



One Small Step for FDA...

FDA is building a knowledge base in nanotechnology and testing its current regulatory procedures. But adapting to the new field could stress the agency's already tight resources and may damage its fragile credibility with the public.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC091271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel